Blood

Local Blood Center Offers Consistent Donation Site for Florence Blood Donors

Wednesday, June 3, 2020 - 2:12pm

The Blood Connection (TBC), a local non-profit, community blood center is now offering blood donors in Florence, SC a more permanent location to donate blood.

Key Points: 
  • The Blood Connection (TBC), a local non-profit, community blood center is now offering blood donors in Florence, SC a more permanent location to donate blood.
  • A blood mobile will be stationed outside of the future TBC Florence Donation Center at 1617 S Irby Street in Florence starting June 1, Monday through Friday from 11 a.m. to 4 p.m.
  • The blood mobile will be available until TBC opens the donation center later this year.
  • All donors who complete a blood donation will receive COVID-19 antibody testing at no cost.

The Global Plasma Protein Therapeutics Market is expected to grow from USD 19,578.09 Million in 2018 to USD 37,938.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.91%

Tuesday, June 2, 2020 - 7:10pm

On the basis of Product, the Global Plasma Protein Therapeutics Market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.

Key Points: 
  • On the basis of Product, the Global Plasma Protein Therapeutics Market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.
  • On the basis of Application, the Global Plasma Protein Therapeutics Market is studied across Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Secondary Immunodeficiency.
  • What are the factors that affect the growth in the Global Plasma Protein Therapeutics Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Plasma Protein Therapeutics Market?

CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program

Friday, May 29, 2020 - 1:02pm

CX-2029 is conjugated to the cytotoxic payload MMAE and is being developed by CytomX in partnership with AbbVie.

Key Points: 
  • CX-2029 is conjugated to the cytotoxic payload MMAE and is being developed by CytomX in partnership with AbbVie.
  • 2 of the partial responses (both at the 3 mg/kg dose) were confirmed after the April 20th cutoff date.
  • No CX-2029 treatment related deaths were reported and late onset Grade 3/4 TRAEs were predominately anemia and neutropenia.
  • CytomX continues to closely monitor emerging Health Authority guidance and IRB/Ethics Committee recommendations and intends to resume the CX-2009 clinical program as soon as practicable.

Global Blood Transfusion Devices Market Analysis 2020-2025 - The Pathogen Reduction System is Expected to Witness Healthy Growth - ResearchAndMarkets.com

Friday, May 29, 2020 - 11:58am

The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The rise in the number of blood disorders, such as anemia, leukopenia, erythrocytosis, leukocytosis, and thrombocytosis is also boosting the blood transfusion market.
  • The pathogen reduction system segment of the blood transfusion market is believed to witness a healthy growrh over the forecast period.
  • Companies like Immucor Inc., Becton Dickinson, B. Braun, Terumo Corporation, and Grifols SA., hold a significant share in the blood transfusion market.

Haemonetics Announces Sale Of U.S. Blood Donor Management Software Solution Assets To The GPI Group

Thursday, May 28, 2020 - 9:18pm

BOSTON, May 28, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell certain blood donor management software solution assets within its Blood Center business unit to the GPI Group (GPI: IM).

Key Points: 
  • BOSTON, May 28, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell certain blood donor management software solution assets within its Blood Center business unit to the GPI Group (GPI: IM).
  • GPI is aleadingcompanyin providing IT Solutions supporting Healthcare and Social Services,listed on the MTAmarket of Borsa Italiana.
  • These products are sold predominantly in the U.S. and provide a range of solutions to optimize blood donor collection centers' blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution.
  • Hemasoft is a U.S. company providing specialized web-based software solutions for blood donor centers, blood banks, transfusion services, cell therapy labs and tissue banks.

Bio Products Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Supply Immediately Available in the United States

Wednesday, May 27, 2020 - 7:29pm

Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.

Key Points: 
  • Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.
  • No cases of transmission of viral diseases or CJD have ever been identified for ALBUMINEX 5% or ALBUMINEX 25%.
  • BPL USA is part of a global company, Bio Products Laboratory, which boasts a vibrant 60-year heritage in plasma research, technology, and manufacturing.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/bio-products-laboratory-announce...
    SOURCE Bio Products Laboratory USA Inc.

Immune Thrombocytopenia Market is Anticipated to Grow by 2030 Owing to a Rich and Robust Pipeline

Wednesday, May 27, 2020 - 3:00pm

The total Immune Thrombocytopenia prevalent population in the 7MM is expected to reach up to184,676in 2020.

Key Points: 
  • The total Immune Thrombocytopenia prevalent population in the 7MM is expected to reach up to184,676in 2020.
  • The Immune Thrombocytopenia market size in the 7MM wasbe USD 2,527.72 million in 2017.
  • The United States is expected to account for the maximum prevalent Immune Thrombocytopenia cases among 7MM countries by 2020.
  • Present Immune Thrombocytopenia Market has several approved therapies that help increasing the count of platelets.

Headspring and PPTA partner to bring a new global plasma donation system to market

Tuesday, May 26, 2020 - 4:23pm

This new system will have a tangible impact on the plasma collection process and the patients who depend on PPTs.

Key Points: 
  • This new system will have a tangible impact on the plasma collection process and the patients who depend on PPTs.
  • Headspring will replace the legacy system and develop and maintain a single, fully responsive web application system that gives plasma collectors seamless access to two databases: the National Donor Deferral Registry (NDDR) and the Cross Donation Check System (CDCS).
  • "PPTA is looking forward to working with Headspring to develop this advanced system," remarked Joshua Penrod, PPTA Senior Vice President, Source and International Affairs.
  • PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors, and patients.

Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

Tuesday, May 26, 2020 - 12:00pm

The biomarker study was conducted using the serum samples of 47 hospitalized COVID-19 patients and 30 healthy controls from Hackensack Meridian Health Network.

Key Points: 
  • The biomarker study was conducted using the serum samples of 47 hospitalized COVID-19 patients and 30 healthy controls from Hackensack Meridian Health Network.
  • LIGHT levels were significantly elevated in the serum of hospitalized patients with COVID-19 versus healthy controls (p value
  • Reducing LIGHT levels might be a key to dampening the cytokine storm in these patients, preventing the need for ventilator support and reducing mortality.
  • Myriad RBM, a subsidiary of Myriad Genetics, Inc., in collaboration with Cerecor has developed an ultrasensitive assay for the detection of free LIGHT.

DGAP-News: Biotest AG: Biotest achieves significant milestone by completing phase I/III clinical trial with fibrinogen

Tuesday, May 26, 2020 - 7:01am

In the phase I/III study, patients with congenital fibrinogen deficiency were treated with the fibrinogen concentrate (BT524) developed by Biotest in the case of acute bleeding or as prophylactic treatment before surgery.

Key Points: 
  • In the phase I/III study, patients with congenital fibrinogen deficiency were treated with the fibrinogen concentrate (BT524) developed by Biotest in the case of acute bleeding or as prophylactic treatment before surgery.
  • These patients are unable to produce functional fibrinogen themselves, or only insufficiently and are therefore dependent on the administration of external fibrinogen.
  • The prospective, open, multicentre phase I/III study investigated the pharmacokinetic properties, efficacy and safety of fibrinogen concentrate in adults and children with congenital fibrinogen deficiency.
  • Biotest is also testing the fibrinogen concentrate in this indication in the phase III trial called "ADFIRST".